Advertisement

Topics

Another Alzheimer’s setback as Amgen, Novartis abandon BACE inhibitor trial

07:59 EDT 12 Jul 2019 | PharmaTimes

Sponsors concluded that the potential benefit for participants in the studies did not outweigh the risk.

Original Article: Another Alzheimer’s setback as Amgen, Novartis abandon BACE inhibitor trial

NEXT ARTICLE

More From BioPortfolio on "Another Alzheimer’s setback as Amgen, Novartis abandon BACE inhibitor trial"

Advertisement
Quick Search
Advertisement
Advertisement